Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

976TiP - SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Ezra Cohen

Citation

Annals of Oncology (2020) 31 (suppl_4): S599-S628. 10.1016/annonc/annonc277

Authors

E.E. Cohen1, L. Dunn2, P. Neupane3, M. Gibson4, R. Leidner5, P. Savvides6, N. Hyland7, T. Trivedi8, M. Dudley9, S. Biswas10, D. Williams11, E. Norry12

Author affiliations

  • 1 Medical Oncology, University of California San Diego, 92093 - San Diego/US
  • 2 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 3 Hematology/oncology, University of Kansas Medical Center, Kansas/US
  • 4 Translational Research For Head And Neck Oncology, Vanderbilt-Ingram Cancer Center, Nashville/US
  • 5 Hematology/medical Oncology, Providence Cancer Institute, Providence/US
  • 6 Hematology & Medical Oncology, Mayo Clinic Arizona, Phoenix/US
  • 7 Clinical Science, Adaptimmune, Philadelphia/US
  • 8 Biometrics, Adaptimmune, Philadelphia/US
  • 9 Early Stage Development, Adaptimmune, Philadelphia/US
  • 10 Oncology Cell Therapies For Solid Tumours, Adaptimmune, OX14 4RX - Abingdon/GB
  • 11 Global Regulatory Affairs, Adaptimmune, 19112 - Philadelphia/US
  • 12 Clinical Development, Adaptimmune, 19112 - Philadelphia/US
More

Resources

Abstract 976TiP

Background

ADP-A2M4 SPEAR T-cells are genetically engineered to target MAGE-A4+ tumors in HLA-A*02 positive patients (pts). Safety and efficacy for ADP-A2M4 cells have been demonstrated in a phase I trial (NCT03132922). MAGE-A4 is frequently expressed in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Pembrolizumab (pembro), an anti-PD-1 checkpoint inhibitor, monotherapy is approved as 1st-line treatment of r/m HNSCC that expresses PD-L1. The combination of ADP-A2M4 and pembro may result in a synergistic effect due to the inhibition of PD-1 on ADP-A2M4 cells potentially leading to deeper and more durable anti-tumor responses.

Trial design

This single-arm trial will enroll up to 10 pts to evaluate efficacy, safety, and tolerability of ADP-A2M4 with pembro. Checkpoint inhibitor naïve r/m HNSCC pts who are HLA-A*02, MAGE-A4+, and PD-L1 positive (≥1%) will be eligible. Part A is a run-in-phase with pembro as standard-of-care monotherapy followed by Part B, an interventional phase, during which ADP-A2M4 will be administered with pembro post-ADP-A2M4 infusion in patients without response or following progressive disease (PD) with pembro in Part A. Part A: Pts will undergo leukapheresis, and collected T-cells will be transduced with a Lentiviral vector expressing a high affinity MAGE-A4 specific T-cell receptor. Pts will receive pembro monotherapy (200 mg IV) every 3 weeks for a minimum of 3 cycles. Disease status will be assessed at Wk 7. Pts without a response by Wk 7 will proceed to Part B. Pts who respond to pembro after 3 cycles will continue treatment in Part A until PD when they will become eligible for ADP-A2M4 treatment in Part B. Part B: Pts will undergo lymphodepleting chemotherapy w/ fludarabine and cyclophosphamide prior to receiving ADP-A2M4 at a dose range of 1x109 to 10x109 transduced T-cells. Pembro infusions every 3 weeks will re-start after ADP-A2M4 infusion and will continue until PD. A Safety Review Committee will review safety and benefit:risk during Part B. Disease will be assessed by investigators per RECIST v1.1 using CT/MRI scans post T-cell infusion.

Clinical trial identification

NCT03132922.

Editorial acknowledgement

Legal entity responsible for the study

Adaptimmune.

Funding

Adaptimmune.

Disclosure

E.E. Cohen: Advisory/Consultancy: ALX Oncology; Advisory/Consultancy: Ascendis; Advisory/Consultancy: Bayer; Advisory/Consultancy: Bioline Rx; Advisory/Consultancy: BMS; Advisory/Consultancy: Debio; Advisory/Consultancy: Dynavax; Advisory/Consultancy: MSD; Advisory/Consultancy: Merck; Advisory/Consultancy: Regeneron. R. Leidner: Advisory/Consultancy: Merck; Advisory/Consultancy: Oncolys; Advisory/Consultancy: Sanofi; Research grant/Funding (institution): Bristol-Myers Squibb. N. Hyland, T. Trivedi, M. Dudley, S. Biswas, D. Williams, E. Norry: Shareholder/Stockholder/Stock options, Full/Part-time employment: Adaptimmune. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings